AAAAAA

   
Results: 1-8 |
Results: 8
UPWARD DRIFT OF (HBA(1C)) - WHATS ITS EFFECT ON COSTS AND COMPLICATIONS IN TYPE-II DIABETES
Authors: CARO JJ KLITTICH W RAGGIO G BOARDMAN P COPLEYMERRIMAN C SIGLER C
Citation: Jj. Caro et al., UPWARD DRIFT OF (HBA(1C)) - WHATS ITS EFFECT ON COSTS AND COMPLICATIONS IN TYPE-II DIABETES, Diabetes, 47, 1998, pp. 1537-1537
MODELING TO ASSESS NEW TREATMENTS FOR TYPE-II DIABETES - APPLICATION AND IMPLICATIONS
Authors: CARO JJ KLITTICH W KAVANAGH P OBRIEN J RAGGIO G COPLEYMERRIMAN C SIGLER C
Citation: Jj. Caro et al., MODELING TO ASSESS NEW TREATMENTS FOR TYPE-II DIABETES - APPLICATION AND IMPLICATIONS, Diabetes, 47, 1998, pp. 1538-1538
EFFECT OF ANTIDEPRESSANT THERAPY ON HEALTH-CARE UTILIZATION AND COSTSIN PRIMARY-CARE
Authors: CROGHAN TW LAIR TJ ENGELHART L CROWN WE COPLEYMERRIMAN C MELFI CA OBENCHAIN RL BUESCHING DP
Citation: Tw. Croghan et al., EFFECT OF ANTIDEPRESSANT THERAPY ON HEALTH-CARE UTILIZATION AND COSTSIN PRIMARY-CARE, Psychiatric services, 48(11), 1997, pp. 1420-1426
MODEL OF COMPLICATIONS OF NIDDM .1. MODEL CONSTRUCTION AND ASSUMPTIONS
Authors: EASTMAN RC JAVITT JC HERMAN WH DASBACH EJ ZBROZEK AS DONG F MANNINEN D GARFIELD SA COPLEYMERRIMAN C MAIER W EASTMAN JF KOTSANOS J COWIE CC HARRIS M
Citation: Rc. Eastman et al., MODEL OF COMPLICATIONS OF NIDDM .1. MODEL CONSTRUCTION AND ASSUMPTIONS, Diabetes care, 20(5), 1997, pp. 725-734
MODEL OF COMPLICATIONS OF NIDDM .2. ANALYSIS OF THE HEALTH BENEFITS AND COST-EFFECTIVENESS OF TREATING NIDDM WITH THE GOAL OF NORMOGLYCEMIA
Authors: EASTMAN RC JAVITT JC HERMAN WH DASBACH EJ COPLEYMERRIMAN C MAIER W DONG F MANNINEN D ZBROZEK AS KOTSANOS J GARFIELD SA HARRIS M
Citation: Rc. Eastman et al., MODEL OF COMPLICATIONS OF NIDDM .2. ANALYSIS OF THE HEALTH BENEFITS AND COST-EFFECTIVENESS OF TREATING NIDDM WITH THE GOAL OF NORMOGLYCEMIA, Diabetes care, 20(5), 1997, pp. 735-744
ECONOMIC VALUE OF GEMCITABINE COMPARED TO CISPLATIN AND ETOPOSIDE IN NON-SMALL-CELL LUNG-CANCER
Authors: COPLEYMERRIMAN C CORRAL J KING K WHITESIDE R VOI M DORR FA MCDONALD RC
Citation: C. Copleymerriman et al., ECONOMIC VALUE OF GEMCITABINE COMPARED TO CISPLATIN AND ETOPOSIDE IN NON-SMALL-CELL LUNG-CANCER, Lung cancer, 14(1), 1996, pp. 45-61
ECONOMIC VALUE OF GEMCITABINE IN NONSMALL CELL LUNG-CANCER
Authors: COPLEYMERRIMAN C MARTIN C JOHNSON N SACRISTAN JA DRINGS PA BOSANQUET N
Citation: C. Copleymerriman et al., ECONOMIC VALUE OF GEMCITABINE IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 23(5), 1996, pp. 90-98
VALUATION OF MEDICAL RESOURCE UNITS COLLECTED IN HEALTH ECONOMIC-STUDIES
Authors: COPLEYMERRIMAN C LAIR TJ
Citation: C. Copleymerriman et Tj. Lair, VALUATION OF MEDICAL RESOURCE UNITS COLLECTED IN HEALTH ECONOMIC-STUDIES, Clinical therapeutics, 16(3), 1994, pp. 553-568
Risultati: 1-8 |